TropIQ

Radboudumc and partners Spin-off companies TropIQ

About TropIQ

TropIQ Health Sciences operates a technology platform for the discovery and development of molecules to combat insect-borne infectious diseases. TropIQ combines world-class parasitological and entomological expertise with state of the art drug discovery technologies. Through this combination, TropIQ is uniquely positioned to accelerate the development of novel medicines, vaccines and vector control measures.

TropIQ details

CEO: Koen Dechering
Affliated department: Medical Microbiology
Researcher: Robert Sauerwein
Year of incorporation: 2012

TropIQ website

News

TropIQ seeks new mosquito repellents

21 September 2021 TropIQ Health Sciences, a Radboudumc spin-off, has received a 1.3 million USD grant from the Bill & Melinda Gates Foundation to track down new mosquito repellents.

967K Euro grant to develop organoids enabling new research methods for skin disorders

11 November 2020 Ellen van den Bogaard will lead a consortium, financed by Health Holland, to establish a platform in which materials and technologies are developed to stimulate research with so-called skin organoids, small pieces of cultured skin.

Rebecca Halbach receives idea generator grant to fight mosquito transmitted viruses

8 July 2020

Rebecca Halbach and Pascal Miesen have investigated in a collaborative project whether the treatment of mosquitoes with antiviral drugs can prevent the transmission of mosquito-transmitted viral diseases.

Radboud-led collaboration generates innovative candidate drug against malaria

19 September 2019

A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the psoriasis drug discovery programme came to a dead end.

Veterinary drug can prevent outbreaks of malaria and Zika in humans

5 July 2018 Drugs that protect pets against ticks and fleas can also be used to prevent outbreaks of malaria, Zika and dengue fever in humans. This was the conclusion of an article by scientists from TropIQ Health Sciences, together with English and American colleagues, and published in the journal PNAS.

EFRO grant for drug development against vector-borne infections

17 July 2017 European Fund for Regional Development (EFRO).

What we do

spin-off companies

contact

news